Non-digestible oligosaccharides (NDO) were shown to reduce @entity32 in experimental @entity1960 , but it remains unclear whether microbiota changes mediate their @entity1960 -modulating effects. This study assessed intestinal microbiota and intestinal @entity32 after feeding chemically defined AIN-76A or @entity35 chow diets, with or without supplementation with 8 g/kg body weight of fructo-oligosaccharides (FOS) or isomalto-oligosaccharides (IMO). The study used HLA-B27 transgenic @entity35 , a validated model of @entity29 ( @entity29 ), in a factorial design with 6 treatment groups. Intestinal @entity32 and intestinal microbiota were analysed after 12 weeks of treatment. FOS and IMO reduced @entity1960 in animals fed @entity35 chow, but exhibited no anti-inflammatory effect when added to AIN-76A diets. Both NDO induced specific but divergent microbiota changes. Bifidobacteria and Enterobacteriaceae were stimulated by FOS, whereas copy numbers of Clostridium cluster IV were decreased. In addition, higher concentrations of total @entity22780 (SCFA) were observed in cecal contents of @entity35 on @entity35 chow compared to the chemically defined diet. AIN-76A increased the relative proportions of @entity4919 , @entity18657 , valerate and @entity9460 irrespective of the oligosaccharide treatment. The SCFA composition, particularly the relative concentration of @entity18657 , @entity9461 and @entity9460 , was associated (P  <= 0.004 and r >=  0.4) with @entity1960 and @entity3426 concentration of the cecal mucosa. This study demonstrated that the protective effects of fibres on @entity1960 development depend on the diet. Although diets modified specific cecal microbiota, our study indicates that these changes were not associated with @entity1960 reduction. Intestinal @entity32 was positively correlated to protein fermentation and negatively correlated with @entity1735 fermentation in the large intestine.

Chemically defined diet alters the protective properties of fructo-oligosaccharides and isomalto-oligosaccharides in HLA-B27 transgenic XXXX .

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity4919 :: ('CHEBI:17272', 'Chemical') :: ['propionate'] @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD'] @entity9461 :: ('CHEBI:17418', 'Chemical') :: ['valerate'] @entity1960 :: ('MESH:D003092', 'Disease') :: ['colitis', 'increased colitis'] @entity9460 :: ('CHEBI:48942', 'Chemical') :: ['iso-valerate'] @entity18657 :: ('CHEBI:16135', 'Chemical') :: ['iso-butyrate'] @entity22780 :: ('MESH:D005232', 'Chemical') :: ['short-chain fatty acids'] @entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity3426 :: ('24494(Tax:10116)', 'Gene') :: ['IL-1 b']
@entity35 :: (10116,Species) :: ['rats']
